Related Experiment Video
Updated: Sep 5, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
Exhalation Delivery System with Fluticasone in Chronic Rhinosinusitis by Eosinophil, Asthma, and Allergy Status
Anju T Peters1, Nithin D Adappa2, Rakesh K Chandra3
1Northwestern University Feinberg School of Medicine, Chicago, IL.
Background:
Chronic rhinosinusitis (CRS) is an inflammatory disease of the nose and paranasal sinuses. Comorbid asthma, environmental allergies, and eosinophilia are associated with CRS. Exhalation delivery system with fluticasone (EDS-FLU) is approved for CRS; however, the influence of these features on treatment response remains unclear.
Objective:
To evaluate whether baseline blood eosinophil (EOS) count, asthma, or allergies affect response to EDS-FLU in patients with CRS.
Methods:
ReOpen1 and ReOpen2 were randomized, EDS-placebo-controlled studies. Patients with CRS were assigned (1:1:1) to EDS-FLU 186 μg, EDS-FLU 372 μg, or EDS-placebo, administered twice daily for 24 weeks. Endpoints included composite symptom score (CSS) at weeks 4, 8, and 12, 22-item Sino-Nasal Outcome Test (SNOT-22) and Patient Global Impression of Change (PGIC) at week 24. Outcomes were analysed for subgroups defined by asthma (yes/no), environmental allergy (yes/no), and EOS count (0-299 vs ≥300 cells/µL).
Results:
Baseline characteristics were similar across groups (N=547). CSS improvement with EDS-FLU vs EDS-placebo was observed across subgroups (LS mean change at week 12 for EDS-FLU vs EDS-placebo in patients with asthma, -2.12 vs -1.36; without asthma, -2.40 vs -1.52; with allergy -2.12 vs -1.24; without allergy -2.37 vs -1.60; with EOS 0-299 cells/µL -2.11 vs -1.56; and with EOS ≥300 cells/µL -2.48 vs -1.36, respectively; all P<0.01). Similar results were observed for SNOT-22 and PGIC. Treatment-by-subgroup interaction showed consistent benefits irrespective of asthma, allergies, or EOS count.
Conclusion:
These results support EDS-FLU as an effective treatment for CRS, independent of underlying inflammatory endotype or common comorbid conditions. Due to the limitations of this analysis, further investigation is warranted.
Trial Registration:
Clinicaltrials.gov Identifiers: NCT03781804 and NCT03960580.
Related Concept Videos
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Inhaled Medications
Asthma I: Introduction
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma III: Clinical Manifestations
Asthma-I: Introduction
